Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Cara Therapeutic
69CCurrent price
0.25 EUR
-0.016 EUR (-5.95%)
Last closed
0.31 USD
Company
www.caratherapeutics.com
ISIN
US1407551092
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
14 698 889 USD
Yield for 12 month
-78.00 %
1Y
3Y
5Y
10Y
15Y
69C
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Address: 400 Atlantic Street, Stamford, CT, United States, 06901
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1.01 USDP/E ratio
–Dividend Yield
–Current Year
+20 968 000 USD
Last Year
+41 867 000 USD
Current Quarter
+991 000 USD
Last Quarter
+2 135 000 USD
Current Year
+14 535 000 USD
Last Year
+34 601 000 USD
Current Quarter
+914 000 USD
Last Quarter
+1 473 000 USD
Key Figures 69C
1 year
3 years
5 years
10 years
EBITDA
-104 724 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-63.43 %
PEG Ratio
–
Return On Equity TTM
-184.32 %
Wall Street Target Price
1.01 USD
Revenue TTM
10 996 000 USD
Book Value
0.21 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-85.7 %
Dividend Yield
–
Gross Profit TTM
-56 141 000 USD
Earnings per share
-2.04 USD
Diluted Eps TTM
-2.04 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 69C
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 69C
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:2
Payout Ratio
–
Last Split Date
16.01.2014
Dividend Date
–
Stock Valuation 69C
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
4.8319
Price Sales TTM
1.3367
Enterprise Value EBITDA
-2.3176
Price Book MRQ
1.2674
Financials 69C
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 69C
For 52 weeks
0.24 USD
1.4 USD
50 Day MA
0.3 USD
Shares Short Prior Month
832 171
200 Day MA
0.53 USD
Short Ratio
1.94
Shares Short
609 721
Short Percent
1.29 %
BeatStart